TY - JOUR AU - Paz-Ares, Luis AU - Garassino, Marina Chiara AU - Chen, Yuanbin AU - Reinmuth, Niels AU - Hotta, Katsuyuki AU - Poltoratskiy, Artem AU - Trukhin, Dmytro AU - Hochmair, Maximilian J. AU - Oezgueroglu, Mustafa AU - Ji, Jun Ho AU - Statsenko, Galina AU - Conev, Nikolay AU - Bondarenko, Igor AU - Havel, Libor AU - Losonczy, György AU - Xie, Mingchao AU - Lai, Zhongwu AU - Godin-Heymann, Nadia AU - Mann, Helen AU - Jiang, Haiyi AU - Shrestha, Yashaswi AU - Goldman, Jonathan W. TI - Durvalumab ± Tremelimumab plus Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden JF - CLINICAL CANCER RESEARCH J2 - CLIN CANCER RES VL - 30 PY - 2024 IS - 4 SP - 824 EP - 835 PG - 12 SN - 1078-0432 DO - 10.1158/1078-0432.CCR-23-1689 UR - https://m2.mtmt.hu/api/publication/34726620 ID - 34726620 N1 - Department of Medical Oncology, Hospital Universitario12de Octubre, Lung Cancer Unit CNIO-H120, Complutense University and Ciberonc, Madrid, Spain Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Department of Medicine, Section of Hematology/Oncology, Thoracic Oncology Unit, University of Chicago, Chicago, IL, United States Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, United States Asklepios Lung Clinic, Member of the German Center for Lung Research (DZL), Gauting, Munich, Germany Okayama University Hospital, Okayama, Japan Petrov Research Institute ofOncology, St. Petersburg, Russian Federation Odessa Regional Oncological Dispensary, Odessa, Ukraine Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria Istanbul University-Cerrahpaşa, Cerrahpaşa School ofMedicine, Istanbul, Turkey Samsung Changwon Hospital, Sungkyunkwan University, School of Medicine, Changwon, South Korea Omsk Regional Cancer Center, Omsk, Russian Federation Clinic of MedicalOncology, UMHAT StMarina, Varna, Bulgaria Dnipropetrovsk Medical Academy, Dnipro, Ukraine Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic Semmelweis University, Budapest, Hungary AstraZeneca, Waltham, MA, United States Astra- Zeneca, Gaithersburg, MD, United States AstraZeneca, Cambridge, United Kingdom David Geffen School of Medicine at UCLA, Los Angeles, CA, United States Cited By :3 Export Date: 15 April 2024 CODEN: CCREF Correspondence Address: Paz-Ares, L.; Hospital Universitario 12 de Octubre, Av de Cordoba s/n, Spain; email: lpazaresr@seom.org Correspondence Address: Shrestha, Y.1 Medimmune Way, AstraZeneca, United States; email: yashaswi.shrestha@astrazeneca.com Chemicals/CAS: carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; durvalumab, 1428935-60-7; etoposide, 33419-42-0, 433304-61-1; ipilimumab, 477202-00-9; nivolumab, 946414-94-4; pembrolizumab, 1374853-91-4; platinum, 7440-06-4; ticilimumab, 745013-59-6; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; durvalumab; Etoposide; Platinum; tremelimumab Funding details: AstraZeneca España Funding text 1: The study was funded by AstraZeneca. AB - Purpose: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB). Experimental design: Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone. Treatment effects in PD-L1 and tTMB subgroups were estimated using an unstratified Cox proportional hazards model. Results: The PD-L1 and tTMB biomarker-evaluable populations (BEP) comprised 54.4% (438/805) and 35.2% (283/805) of the intention-to-treat population, respectively. PD-L1 prevalence was low: 5.7%, 25.8%, and 28.3% had PD-L1 expression on >= 1% tumor cells (TC), >= 1% immune cells (IC), and >= 1% TCs or ICs, respectively. OS benefit with durvalumab plus EP versus EP was similar across PD-L1 subgroups, with HRs all falling within the 95% confidence interval (CI) for the PD-L1 BEP (0.47-0.79). OS benefit with durvalumab plus tremelimumab plus EP versus EP was greater in PD-L1 >= 1% versus <1% subgroups, although CIs overlapped. There was no evidence of an interaction between tTMB and treatment effect on OS (durvalumab plus EP vs. EP, P = 0.916; durvalumab plus tremelimumab plus EP vs. EP, P = 0.672). Conclusions: OS benefit with first-line durvalumab plus EP in patients with ES-SCLC was observed regardless of PD-L1 or tTMB status. PD-L1 expression may prove to be a useful biomarker for combined treatment with PD-(L)1 and CTLA-4 inhibition, although this requires confirmation with an independent dataset. See related commentary by Rolfo and Russo, p. 652. LA - English DB - MTMT ER - TY - JOUR AU - Csósza, Györgyi AU - Szűcs, Gergő AU - Rozgonyi, Zsolt Dezső AU - Csoma, Balázs AU - Losonczy, György AU - Müller, Veronika AU - Karlócai, Kristóf AU - Lázár, Zsófia TI - Circulating apelin, IL22RA2 and VEGF in pre-capillary pulmonary hypertension JF - PHYSIOLOGY INTERNATIONAL J2 - PHYSIOL INT VL - 110 PY - 2023 IS - 4 SP - 356 EP - 370 PG - 15 SN - 2498-602X DO - 10.1556/2060.2023.00264 UR - https://m2.mtmt.hu/api/publication/34441154 ID - 34441154 N1 - Department of Pulmonology, Semmelweis University, Budapest, Hungary Department of Anaesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary Export Date: 11 April 2024 Correspondence Address: Lázár, Z.; Department of Pulmonology, Hungary; email: lazar.zsofia@med.semmelweis-univ.hu Chemicals/CAS: growth hormone, 36992-73-1, 37267-05-3, 66419-50-9, 9002-72-6; iloprost, 78919-13-8, 82889-99-4, 697225-02-8; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; vasculotropin, 127464-60-2; vasculotropin A, 489395-96-2; Apelin; Biomarkers; Cytokines; IL22RA2 protein, human; Receptors, Interleukin; Vascular Endothelial Growth Factor A Manufacturers: Mindray, China; RayBiotech, United States Funding details: MPA/2019 Funding text 1: We thank Tímea Baranyi for assistance in collecting clinical data. This work was supported by the Hungarian Respiratory Foundation to Dr. Györgyi Csósza [grant number MPA/2019]. LA - English DB - MTMT ER - TY - JOUR AU - Liu, S.V. AU - Mok, T.S.K. AU - Nabet, B.Y. AU - Mansfield, A.S. AU - De, Boer R. AU - Losonczy, György AU - Sugawara, S. AU - Dziadziuszko, R. AU - Krzakowski, M. AU - Smolin, A. AU - Hochmair, M.J. AU - Garassino, M.C. AU - Gay, C.M. AU - Heymach, J.V. AU - Byers, L.A. AU - Lam, S. AU - Cardona, A. AU - Morris, S. AU - Adler, L. AU - Shames, D.S. AU - Reck, M. TI - Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide JF - LUNG CANCER J2 - LUNG CANCER-J IASLC VL - 186 PY - 2023 PG - 10 SN - 0169-5002 DO - 10.1016/j.lungcan.2023.107418 UR - https://m2.mtmt.hu/api/publication/34314284 ID - 34314284 N1 - Funding Agency and Grant Number: F. Hoffmann-La Roche Ltd./Genentech Inc. Funding text: This study was sponsored by F. Hoffmann-La Roche Ltd./Genentech Inc., a member of the Roche Group. The sponsor provided the study drugs and support for the trial, and collaborated with authors on study design, data collection, data analyses, and data interpretation. Editorial support, funded by the sponsor, was provided by an independent medical writer under the guidance of the authors. LA - English DB - MTMT ER - TY - JOUR AU - Vámos, Melinda AU - Kolozsvári, Dóra AU - Varga, János Tamás AU - Müller, Veronika AU - Losonczy, György TI - Deszaturációhoz és tudatzavarhoz vezető súlyos dinamikus hiperinfláció vagy asthmás roham bronchiectasiában? JF - REHABILITÁCIÓ: A MAGYAR REHABILITÁCIÓS TÁRSASÁG FOLYÓIRATA J2 - REHABILITÁCIÓ VL - 33 PY - 2023 IS - 2-3 SP - 157 EP - 157 PG - 1 SN - 0866-479X UR - https://m2.mtmt.hu/api/publication/34214284 ID - 34214284 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kolozsvári, Dóra AU - Vámos, Melinda AU - Varga, János Tamás AU - Müller, Veronika AU - Losonczy, György TI - Sikeres fizioterápia extrém mértékű és fulladásos rohamhoz is vezető nyugalmi hiperinflációban öröklött bronchiectasiás fiatalemberben JF - REHABILITÁCIÓ: A MAGYAR REHABILITÁCIÓS TÁRSASÁG FOLYÓIRATA J2 - REHABILITÁCIÓ VL - 33 PY - 2023 IS - 2-3 SP - 135 EP - 135 PG - 1 SN - 0866-479X UR - https://m2.mtmt.hu/api/publication/34214276 ID - 34214276 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Losonczy, György TI - A bakteriális lizátum OM-85 hatása ismétlődő légúti fertőzésekben, asthma bronchiale-ban és COPD-ben JF - MEDICINA THORACALIS (BUDAPEST) J2 - MED THORAC (BP) VL - 76 PY - 2023 IS - 3 SP - 163 EP - 166 PG - 4 SN - 0238-2571 UR - https://m2.mtmt.hu/api/publication/34162695 ID - 34162695 LA - Hungarian DB - MTMT ER - TY - CONF AU - Kolozsvári, D AU - Pintér, R AU - Szőllősi, Gergő József AU - Kup, KA AU - Szarvas, Zsófia AU - Fekete, Mónika AU - Jáky-Kováts, Zsuzsanna Ágnes AU - Horváth, Gábor AU - Losonczy, György AU - Müller, Veronika AU - Varga, János Tamás ED - Pápai-Székely, Zs TI - A 6-perces sétateszt javulásának összefüggése a funkcionális és életminőség paraméterekkel a poszt-COVID rehabilitációban T2 - MTT PULMO 2023 PB - Magyar Tüdőgyógyász Társaság C1 - Kecskemét PY - 2023 SP - 76 EP - 77 PG - 2 UR - https://m2.mtmt.hu/api/publication/34025076 ID - 34025076 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Lazar, Jozsef AU - Antal-Szalmás, Péter AU - Kurucz, Istvan AU - Ferenczi, Annamaria AU - Józsi, Mihály AU - Tornyi, Ilona AU - Muller, Monika AU - Fekete, János Tibor AU - Lamont, John AU - FitzGerald, Peter AU - Gall-Debreceni, Anna AU - Kádas, János AU - Vida, András AU - Tardieu, Nadege AU - Kieffer, Yann AU - Jullien, Anne AU - Guergova-Kuras, Mariana AU - Hempel, William AU - Kovacs, Andras AU - Kardos, Tamas AU - Bittner, Nóra AU - Csanky, Eszter AU - Szilasi, Mária AU - Losonczy, György AU - Szondy, Klára AU - Gálffy, Gabriella AU - Csada, Edit AU - Szalontai, Klára Margit AU - Somfay, Attila AU - Malka, David AU - Cottu, Paul AU - Bogos, Krisztina AU - Takacs, Laszlo TI - Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer Biomarkers JF - MOLECULAR & CELLULAR PROTEOMICS J2 - MOL CELL PROTEOMICS VL - 22 PY - 2023 IS - 7 PG - 20 SN - 1535-9476 DO - 10.1016/j.mcpro.2023.100580 UR - https://m2.mtmt.hu/api/publication/33999296 ID - 33999296 N1 - Biosystems International Kft., Debrecen, Hungary Biosystems Immunolab Zrt., Debrecen, Hungary Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary MTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), Budapest, Hungary Department of Human Genetics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Adware Research Kft., Balatonfüred, Hungary Department of Bioinformatics, Semmelweis University, Budapest, Hungary Randox Laboratories Ltd, Crumlin, United Kingdom Bio-systems International SAS, Evry, France Department of Pulmonology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Department of Pulmonology, Miskolc Semmelweis Hospital, University Hospital, Miskolc, Hungary Department of Pulmonology, Faculty of Medicine, Semmelweis University, Budapest, Hungary Csongrád County Hospital of Chest Diseases, Deszk, Hungary Department of Pulmonology, Faculty of Medicine, University of Szeged, Deszk, Hungary Department of Medical Oncology, Gustave Roussy, Villejuif, France Department of Medical Oncology, Institut Curie, Paris, France National Koranyi Institute for Pulmonology, Budapest, Hungary Cited By :2 Export Date: 14 March 2024 CODEN: MCPOB Correspondence Address: Lazar, J.; Biosystems International Kft.Hungary; email: jozsef.lazar@biosys-ilab.com Correspondence Address: Takacs, L.; Biosystems International Kft.Hungary; email: laszlo.takacs@biosys-ilab.com LA - English DB - MTMT ER - TY - BOOK AU - Szűcs, Gergő AU - Szentkereszty, Márton AU - Tóvári, István AU - Ladányi, Andrea AU - Gálffy, Gabriella AU - Losonczy, György TI - A BMI és a túlélési idő közötti összefüggés korai stádiumú NSCLC-ben PY - 2023 UR - https://m2.mtmt.hu/api/publication/33925652 ID - 33925652 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Horváth, Péter AU - Büdi, Lilla AU - Hammer, Dániel AU - Varga, R. AU - Losonczy, György AU - Tárnoki, Ádám Domonkos AU - Tárnoki, Dávid László AU - Mészáros, M. AU - Bikov, András TI - The link between the sphingolipid rheostat and obstructive sleep apnea JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 13 PY - 2023 IS - 1 PG - 8 SN - 2045-2322 DO - 10.1038/s41598-023-34717-4 UR - https://m2.mtmt.hu/api/publication/33861253 ID - 33861253 N1 - Funding Agency and Grant Number: Semmelweis University Funding text: Open access funding provided by Semmelweis University. AB - Chronic inflammation induced by hypoxia during sleep is an important mechanism of microvascular damage in OSA patients. In this study, we investigated the role of the sphingosine rheostat, which has diverse inflammatory effects. Thirty-seven healthy subjects and 31 patients with OSA were recruited. We collected data on demographics and comorbidities. Plasma sphingosine-1-phosphate and ceramide antibody concentrations were measured by ELISA. The results were compared between the OSA and control groups, and the correlations between these measurements and markers of disease severity and comorbidities were explored. Ceramide antibody levels were significantly elevated in OSA patients (892.17 ng/ml) vs. controls (209.55 ng/ml). S1P levels were also significantly higher in patients with OSA (1760.0 pg/ml) than in controls (290.35 pg/ml, p < 0.001). The ceramide antibody concentration showed correlations with BMI (ρ = 0.25, p = 0.04), CRP (ρ = 0.36, p = 0.005), AHI (ρ = 0.43, p < 0.001), ODI (ρ = 0.43, p < 0.001), TST90% (ρ = 0.35, p = 0.004) and the lowest oxygen saturation (ρ = 0.37, p = 0.001) in the whole study population but not when patients with OSA were analyzed separately. The elevated ceramide antibody and sphingosine-1-phosphate concentrations in patients suffering from OSA suggests their involvement in the pathomechanism of OSA and its comorbidities. © 2023, The Author(s). LA - English DB - MTMT ER -